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2Abstract
Glial cell line-derived neurotrophic factor (GDNF) was assayed for its neurotrophic effects
against the neuronal atrophy that causes cognitive deficits in old age. Aged Fisher 344 rats
with impairment in the Morris water maze received intrahippocampal injections at the
dorsal CA1 area of either a lentiviral vector encoding human GDNF or the same vector
encoding human green fluorescent protein as a control. Recombinant lentiviral vectors
constructed with human cytomegalovirus promotor and pseudotyped with lyssavirus
Mokola glycoprotein specifically transduced the astrocytes in vivo. Astrocyte-secreted
GDNF enhanced neuron function as shown by local increases in synthesis of the
neurotransmitters acetylcholine, dopamine and serotonin. This neurotrophic effect led to
cognitive improvement of the rats as early as two weeks after gene transduction. Spatial
learning and memory testing showed a significant gain in cognitive abilities due to GDNF
exposure, whereas control-transduced rats kept their performance at the chance level. These
results confirm the broad spectrum of the neurotrophic action of GDNF and open new gene
therapy possibilities for reducing age-related neurodegeneration.
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31. Introduction
Glial cell line-derived neurotrophic factor (GDNF) is a member of the transforming growth
factor  superfamily. It was first isolated from culture medium of rat B49 glioblastoma
cells in a search of trophic factors for midbrain dopaminergic neurons [73,74]. GDNF has
remarkable regenerative and restorative effects upon nigrostriatal dopaminergic neurons
[16,46,51]. Soon after its discovery, it was found that GDNF is a potent neurotrophic factor
active on a broad spectrum of neuronal types and has neuroprotective effects in several
experimental paradigms of nerve cell injury. For instance, GDNF reduces neuronal damage
in axotomized neurons [56,96,121,126], in experimental brain trauma [7] and ischemia
[23,64,87,122], and in several excitotoxic [78,92,100,124] and neurotoxic injuries
modeling neurodegenerative diseases [6,50,119]. Therapeutic GDNF administration has
raised expectations that it could be a preventive or palliative treatment for Parkinson’s
disease [for review see: 35,38], amyotrophic lateral sclerosis [for review see: 12,82] and
Huntington’s disease [for review see: 3].
GDNF is expressed in both neurons and astrocytes [73,77,92,108]. It signals
through the two-component receptor complex GFR-/Ret [118], also expressed in both
cell types [92]. An increase in astrocyte GDNF synthesis and protein expression is believed
to play an active role in neuron survival and plasticity after ischemia [88,117] and
excitotoxic damage [60,77]. Accordingly, experimental strategies of GDNF delivery by
astrocytes have shown to be neuroprotective in vivo for motor neurons [97,128] and
dopaminergic neurons [29,31,34].
Endogenous GDNF plays an important role in cognitive abilities as demonstrated by
the impaired spatial learning performance of mice that are heterozygous for a targeted
deletion of the GDNF gene [49]. Spatial learning and memory is associated with intact
hippocampus function and it has long been known that memory deficits in old age are
similar to those produced by bilateral hippocampal lesions [18,52]. Different categories of
agents, such as neurotrophins [40,41,79], antioxidant agents [72,94] and cholinergic drugs
[13,58], have been assayed in aged rodents in a search for effective and harmless treatments
that reverse the memory loss of normal aging and ameliorate memory loss in pathological
4aging caused by Alzheimer’s disease. The potential of GDNF against age-related cognitive
deterioration has not been fully explored. In a previous study, spatial learning and memory
improved in aged rats after i.c.v. administration of GDNF but no brain regional correlates
were analyzed [99]. We studied the restorative effects of GDNF on spatial learning and
memory after local delivery into the hippocampus. For this purpose, the astrocytes of the
dorsal CA1 hippocampal area of cognitively impaired aged Fisher 344 rats were transduced
in vivo with a lentiviral vector expressing the human gene for GDNF. The efficacy of
transgene delivery, either GDNF or the human green fluorescent protein (GFP) used as a
control, and the behavioral and neurotransmitter changes shown by the aged rats were
determined throughout the study. Brain regional GDNF gene expression allowed the
evaluation of the involvement of the hippocampal CA1 function in maintaining spatial
learning and memory through aging. Vector specificity for the GDNF gene transfer to
astrocytes enabled the study of the neuroprotective potential of these glial cells in
neurodegenerative processes.
2. Methods
2.1. Animal groups
Thirty male 7-month old Fisher 344 rats retired from breeding were purchased from
Charles River (Lyon, France) and kept in the animal house of the University of Barcelona
until they were old. They were maintained in standard conditions of temperature and
humidity, with two animals per cage, a 12:12 h light-dark cycle, and food and water ad
libitum. Only animals showing a healthy general status at 22 months of age were included
in the study. A group of 10 young male rats of the same origin were used to test the viral
stock. A further group of 10 6-month old male Fisher 344 rats were included in the study
for comparative neurotransmitter determinations. All handling and experimental procedures
were approved by the Animal Ethics and Health Committees of the University of
Barcelona.
52.1. Lentiviral vectors
A recombinant lentiviral vector encoding human GDNF was constructed for the specific
transduction of astrocytes in vivo. The combination of the lyssavirus Mokola glycoprotein
(Mokola G) pseudotype with the human cytomegalovirus promoter (CMV) allowed
efficient transgene expression under these experimental conditions. A vector encoding GFP
instead of GDNF was used as a control vector. Vectors were constructed and produced as
previously described [10,91]. Briefly, the plasmids Flap-CMV-GDNF-WPRE and Flap-
CMV-GFP-WPRE were derived from the lentiviral vector genome. These plasmids contain
the backbone of the lentiviral genome including the central Flap sequence [127]. The
GDNF and GFP transgenes were under control of the CMV promoter. The woodchuck
hepatitis virus post-transcriptional regulatory element (WPRE) was added 3 to the GDNF
or GFP gene to increase transgene expression [129]. Lentiviral vector stocks were produced
by transient co-transfection of 293T cells with the vector genome plasmid, a packaging
plasmid and a plasmid coding for the envelope that included the Mokola G gene. The cell
supernatant for each transgene vector was harvested 48 h post-transfection, treated with
DNase, filtered through 0.45 µm pore-sized filters, and subjected to ultra-centrifugation at
64,000 x g for 90 min. The virus pellet was resuspended in phosphate-buffered saline
(PBS) and its physical titer was quantified by ELISA of the p24 capsid protein. Viral stocks
were kept at -80ºC until use. At that moment, stocks were diluted with PBS to 30 ng/l of
p24 protein.
2.3. Behavioral testing
The behavioral test for spatial learning and memory was performed in a Morris water maze
[89]. The apparatus was modeled as described elsewhere [22]. Briefly, it measured 1.60 m
in diameter and water was made opaque by the addition of 100 mL/L of latex. Water
temperature was maintained at 22±1ºC. Black curtains surrounded the pool. Inside the
black enclosure four landmarks hanging from a false black ceiling defined the position of
the hidden platform: A, a 40-W fixed light; B, a beach ball with horizontal color drawings;
6C, a vertical white structure with three truncated cones of decreasing size; and D, three
silver bottles bound by their neck. Landmark objects were hung at 90º distance. The
platform has a diameter of 0.11 m and was placed between landmarks A and B, 1 cm below
the surface and 0.38 m from the side. The landmarks and the platform were semi-randomly
rotated with respect to the room (90º, 180º, 270º, 360º) in a daily-equated way in order to
ensure that the rats used these landmarks, rather than any inadvertently remaining static
room cue, to locate the platform. A closed-circuit video camera recorded rat movements
that were analyzed by computer. A pre-training test with the platform made visible, located
1 cm above the water surface, consisted of 8 trials during 2 days. The rat was given 90 s to
find the platform, and then allowed to stay on for 30 s. When the rat did not reach the
platform, it was picked up, placed on it and left there for 30 s. Rats that failed to find the
visible platform were discarded from the study. For the acquisition test, the procedure was
the same, but animals had to rely on the landmarks to find the hidden platform. Animals
were given 4 escape trials per day for 12 days, a total of 48 trials. Latencies to reach the
escape platform were recorded for each trial and averaged for the 4 daily trials. On the last
day, a 60 s probe trial was performed with the platform removed. To analyze the rat’s
behavior, the surface of the pool was divided into four quadrants and the time that the rat
spent in the quadrant where the platform was previously was calculated. Impaired aged rats
were defined as those spending a time not different from chance performance (15 s out of
60 s) in the right quadrant during the spatial probe trial. Two weeks later, the impaired
animals were divided in two groups that were treated for hippocampal astrocyte expression
of GFP and GDNF, respectively (see surgical procedures below). Test assays were initiated
two weeks after surgery, when rats were nearly 24 months old. Animals were given 4
escape trials per day and on the fourth day a probe trial was performed. This procedure
continued, with a probe trial every four days until 48 escape trials had been conducted.
Behavioral results for rats that did not survive until the end of the study were not included.
2.3. Surgical procedures
A total of 23 aged rats underwent surgery: 7 rats of the GFP group, 8 rats of the GDNF
7group and 8 unimpaired rats. Animals were anesthetized with 10 mg/kg xylacine (Rompun
2%, Bayer) and 80 mg/kg ketamine (Ketolar 50 mg/ml, Pfizer) i.m., and placed in a
stereotactic apparatus. Bilateral infusions were performed into the CA1 area of the
hippocampus at the coordinates: anterior-posterior –3.8 mm, medio-lateral +/-2 mm and
dorso-ventral –2.4 mm, from bregma and dural surface. The right coordinates to reach were
previously checked in 3 animals discarded from the study. One l of the vector solution
was delivered to the application point with a 25-gauge stainless steal cannula (Small Parts
Inc., Miami, FL) connected to a Hamilton syringe through a Teflon tube. The syringe was
attached to a micro-infusion pump (Bioanalytical systems Inc., West Lafayette, IN). The
cannula was left in position for 5 min after delivery to prevent the solution from surging
back.
2.4. Brain dissection and histology
After completion of the behavioral studies, animals were decapitated under light anesthesia
with 40 mg/kg ketamine. Brains were quickly removed, immersed in cold saline solution
and placed in a Kopf brain blocker. The cerebrum was cut into three blocks and then
bisected sagittaly at the midline. A block containing the half dorsal hippocampal area of
selected animals from the GFP group was fixed by immersion in 10% phosphate buffered
formaldehyde, cryoprotected with 10% sucrose and frozen on a stainless steel plate over
dry ice. Slices 16 m thin were double-stained with the antibodies against GFP 1:1000
(polyclonal, Abcam, Cambridge, UK) and GFAP 1:400 (monoclonal, clone GA5, Sigma,
St. Louis, MO), as previously described [10]. Secondary antibodies used were Alexa Fluor
488 1:1000 and Alexa Fluor 546 1:1000, respectively (Molecular Probes, Eugene, OR).
Nuclei were counterstained with bisbenzimide (Sigma). For all other animals, both
hemispheres were further dissected on a chilled glass plate, according to the procedure
described in detail elsewhere [8]. Tissue samples for 6 hippocampal areas (dorsal and
ventral CA1, dorsal and ventral CA2/3, dorsal and ventral dentate gyrus), 5 cerebral cortical
areas (cingulate, frontal, temporal, entorhinal, parietal), septum and caudate [98], were
weighed and frozen at –80ºC until analysis.
82.6. GDNF determination
The level of GDNF expression of the viral stock under the injection conditions used was
tested in a group of 10 young rats of the same colony used for the experiment. A
microinjection of the GDNF vector was performed in the dorsal CA1 area of the right
hippocampus as described above. GFP vector was injected on the left side of half the
animals and the other half were untreated. Rats were killed a week later, and the
hippocampus dissected as described above. Regional tissue levels of GDNF were
determined by ELISA with the GDNF Emax ImmunoAssay System kit (Promega), following
the manufacturer’s instructions. Long-term stability of this viral stock was previously
checked and expression was stable for one year (unpublished data).
2.5. Choline acetyl transferase and monoamine neurotransmitter determinations
Choline acetyl transferase (ChAT) activity in the tissue samples was measured by the
formation of 14[C]acetylcholine from 14[C]acetylcoenzyme-A (60 mCi/mmol; New England
Nuclear, PerkinElmer, Wellesley, MA) and choline (Sigma). For this purpose, homogenates
from left cerebral hemisphere regions were processed following the procedure described
elsewhere [5].
The monoamine neurotransmitters, dopamine and serotonin, the acid metabolites of
dopamine 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) and the
acid metabolite of serotonin 5-hydroxiindoleacetic (5-HIAA) were analyzed in the right
hemisphere tissue samples of GFP, GDNF and young rat groups. Tissue samples were
homogenized in a cold solution of 0.4 M perchloric acid, 0.01 % EDTA, 0.1 % sodium
bisulfite and 0.01 % cystine and centrifuged at 12000 x g for 30min. The concentrations of
neurotransmitters and metabolites in supernatants were determined by HPLC using a 3-µm
octadecylsilica (ODS) column (7.5 cm x 0.46 cm; Beckman) and detected
amperometrically with a Hewlett-Packard 1049 detector set at oxidation potentials of 0.6 V
9(serotonin and 5-HIAA) and 0.7 V (dopamine, DOPAC and HVA). The mobile phase for 5-
HT consisted of 0.15 M NaH2PO4, 1.8 mM octyl sodium sulfate, 0.2 mM EDTA (pH 2.8
adjusted with phosphoric acid) and 30 % methanol. The mobile phase for dopamine
consisted of 0.15 M NaH2PO4, 0.46 mM octyl sodium sulfate, 0.5 mM EDTA (pH 2.8
adjusted with phosphoric acid), and 18 % methanol. Both mobile phases were pumped at
0.7 mL/min. Quantitative analyses were performed by the external standard method.
2.7. Statistics
Results are expressed as mean ± SEM. Statistical evaluation was performed with ANOVA
procedures, followed by Bonferroni’s or Newman-Keules’s multi-range test for comparison
of the mean group values.
3. Results
3.1. Astrocyte transduction with GFP and GDNF
The injection of lentiviral particles aimed at the dorsal CA1 hippocampal area yielded a
wide GFP expression mainly in the stratum radiatum and also in the oriens layer of this
area. No expression was detected beyond the hippocampus. Transduced proteins were
selectively expressed in astrocytes as demonstrated by overlapping of GFP and GFAP
immunostaining whereas no GFP expression was detected in the neurons of the pyramidal
molecular layer (GFP transduced rats, Fig. 1a-g). In a parallel study, we have confirmed the
astrocyte specific expression of the GFP reporter gene with the presently used vector in
several animal species (mouse, rat and non-human primate; Brizard et al., unpublished
observations).
The ability of the GDNF-engineered lentiviral vector to drive a detectable production of
GDNF was previously confirmed in a separate group of animals. GDNF levels determined
by ELISA were higher in the dorsal CA1 transduced with GDNF than in the GFP-
transduced or untreated CA1 area of the contralateral side (Table 1). A lesser GDNF over-
expression was detected in the ipsilateral adjacent area CA2/3.
10
3.2. Improved performance of GDNF injected rats in the Morris water maze
Timing of the behavioral studies is indicated in Fig. 2a. The aged animals were clearly
classified as non-impaired or learning-impaired, according to the results of the pre-test
spatial probe trial (Fig. 2b, probe trial 0). Non-impaired rats spent 27.8 ± 3.6 s (n=8) and
impaired rats spent 15.5 ± 4.3 s (n=15) out of the 60 s in the pool quadrant that previously
contained the platform (p<0.0001 and p=0.6746 as against to chance value of 15 s,
respectively). During prior training, latencies to find the hidden escape platform decreased
steadily without significant group differences (two-way ANOVA, effect of day factor:
F(11,211)=4.915, p<0.0001) (Fig 2c).
In the spatial probe trials after surgery, the GDNF group showed steady learning
improvement that was not present in the GFP group (Fig. 2b, probe trials 1-3). The latter
rats kept their values of searching time in the correct quadrant at the chance level. By the
end of the test-training period, GDNF rats showed values close to the unimpaired control
group. The performance differences between GFP- and GDNF-injected rats were
significant (ANOVA, F(1,44)=9.869, p=0.0030). No differences of latency to find the
hidden platform during the 12 training days were detected between the two rat groups (Fig.
3d).
The swim speed was not affected by either the surgery or the transgene expression.
Pre-surgery values measured in the pre-test probe trial were 21.58 ± 1.24 cm/s for the non-
impaired rats, 21.61 ± 0.69 cm/s for the GFP group and 21.83 ± 0.81 cm/s for the GDNF
group. Final swim speed measured in the last test probe trial was 22.73 ± 0.69 cm/s and
21.89 ± 1.07 cm/s for the GFP and the GDNF groups, respectively.
3.3. Increase of neurotransmitter levels in the hippocampus after GDNF transduction
Tissue concentration of ChAT, indicative of acetylcholine levels, in selected brain regions
of young and aged impaired rats is shown in Fig. 3a (hippocampus areas) and Table 2 (all
brain areas assayed). Two-way ANOVA indicated an effect of the cerebral brain region
(F(12,180)=14.50, p<0.0001) and of the rat group (F(2,180)=7.56, p=0.0007). By paired
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ANOVA testing, GDNF rat group was significantly different from GFP and from young rat
groups (not shown). In GDNF transduced rats, an increase was detected in the whole CA1
area, as against GFP rats; whereas the ventral part increased also over young rat values.
Cingulate cortex ChAT increased in GDNF rats over the other two groups. There was a
decrease in the ventral CA2/3 area of GDNF rats, as against the group of young rats.
Regional brain concentration of dopamine is shown in Fig. 3b (hippocampus areas)
and Table 3 (all brain areas assayed) and its metabolites DOPAC and HVA are shown in
Table 3. Two-way ANOVA for brain region and rat group indicated an effect of the brain
region factor for the concentration of dopamine and its metabolites (not shown), whereas
the rat group factor was significant for both metabolites DOPAC (F(2,321)=12.98,
p<0.0001) and HVA (F(2,319)=71.59, p<0.0001). The group effect was significant for
dopamine levels when the brain regions were restricted to the hippocampus
(F(2,108)=15.81, p<0.0001). In this area, the increase of dopamine shown by the GDNF
group was significant in the dorsal CA1 area and in the whole dentate gyrus, as against the
group of young rats. A decrease of HVA in both aged GFP and GDNF groups was
observed in the dorsal CA1 and CA2/3, cerebral cortical areas and septum. In the caudate
region of both aged rat groups there was a decrease in both metabolites, DOPAC and HVA.
Regional brain concentration of serotonin is shown in Fig. 3c (hippocampus areas)
and Table 4 (all brain areas assayed) and its metabolite 5-HIAA is shown in Table 4. Two-
way ANOVA showed an effect of brain region (not shown) and rat group for serotonin and
5-HIAA (F(2,319)=25.45, p<0.0001 and F(2,319)=13.91, p<0.0001, respectively). The
GDNF group increased serotonin levels in the whole dorsal hippocampus and in the ventral
dentate gyrus more than the GFP group. Both groups of aged rats showed a hippocampal
increase of 5-HIAA in the dorsal dentate gyrus and the ventral CA1 area. Serotonin also
increased in cingulate and temporal cortical areas and in the caudate of control GFP aged
rats, as against to young rats.
4. Discussion
The over-expression of GDNF in hippocampal astrocytes induced a recovery of spatial
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cognitive abilities in aged impaired rats as demonstrated by an enhancement of memory
retention of the platform location in the test probe trials. This better response in the Morris
water maze cannot be attributed to a mere improvement of age-related motor impairment
by GDNF. Several studies have shown that GDNF enhances motor function in aged rats
and non-human primates, which has been related to dopaminergic induction and
regeneration of the nigrostriatal pathway [15,33,53,57,69]. In the present study, GDNF was
over-expressed only in a restricted area of the hippocampus and no changes were induced
in the swimming speed. In addition, we found no differences in the latency to escape
between the rats expressing GDNF and control rats transduced with GFP during the test
assays, where an increase in swimming ability would help the rats to find the platform in a
shorter time. Latency to escape to the platform is routinely recorded as an additional spatial
learning and memory measure, but its outcome can be affected by external factors. This is
not the case with probe trial performance, which is accepted as the most accurate
measurement because it requires memory of the precise location of the platform [19,42].
Accordingly, in previous studies in our behavioral facilities, the probe trial was established
as a reliable result for learning acquisition and retention under our experimental conditions
[103].
The present results confirm the previous report of a significant recovery of cognitively
impaired two-year old Fisher 344 rats in the Morris water maze two weeks after an i.c.v.
injection of GDNF [99]. The degree of spatial learning recovery after a GDNF transgene
expression in dorsal CA1 astrocytes was similar to that obtained by earlier authors. Spatial
learning and memory require the dorsal hippocampus to function [25,102], with the CA1
area being particularly crucial for spatial discrimination tasks [90,120]. In old age, CA1
pyramidal neurons suffer a loss of functional synaptic contacts from the Schaffer collaterals
and an alteration in Ca2+ regulation, both changes leading to plasticity and cognition deficits
[59,105,116]. The absence of a generalized loss of cells and synapses in the hippocampus
and the whole brain in normal aging [61,85] facilitates amelioration of cognitive decline by
neurotrophic action. Both GFR1 and Ret receptor molecules are highly expressed in the
hippocampal neurons of the pyramidal layer of the Ammon’s horn [20,107,111]. Therefore,
GDNF secreted by CA1 transduced astrocytes was able to exert its trophic action on local
neurons. Ectopic fiber sprouting is unlikely because GDNF secreted by transduced
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astrocytes is not or very poorly transported by neurons to distal areas [34] (Mammeri H. et
al., unpublished observations). Nevertheless, a histological study should be performed
when a long-lasting GDNF gene expression in hippocampus is planned to fully discard the
possibility of unwanted effects in projection areas.
Neurochemical changes in cognitively impaired aged rats have been extensively
studied in a search for the causes underlying frequent memory loss in older individuals.
Atrophy of acetylcholine containing neurons is considered a hallmark of aging and
dementia [115], but this cholinergic dysfunction occurs within a wider context of
neurotransmitter system changes [30,114]. Cholinergic and monoaminergic
neurotransmitter systems are involved in the spatial learning and memory processes in the
hippocampus [32,37,84,104,109]. Hippocampus is a target cholinergic area and no local
decrease of ChAT activity was reported in aged rats, confirming our results, whereas ChAT
decreases have been found in the cholinergic cell body containing areas of the basal
forebrain and striatum in cognitively impaired rats [43]. Hippocampus receives its
dopaminergic innervation from the midbrain and is integrated in the mesolimbic system.
Many studies have demonstrated an age-related decline in dopaminergic neurotransmission,
mainly in the nigrostriatal system [43,71,86]. In addition, decreased density of dopamine
receptors D1 to D5 have been reported in several brain areas, including the hippocampus of
aged rat and human [4,55,63]. We found a widespread decrease of dopamine metabolite
HVA in aged rats, indicative of a lower turnover rate. The effect was higher in the caudate,
in which both metabolites, DOPAC and HVA, decreased. The role of the serotonergic
system in aging impairment has raised controversy. Several authors have reported
unchanged or enhanced serotonin levels and turnover in aged rats [43,71], while others
reported decreases [86]. Confirming the former we found a trend to higher serotonin and 5-
HIAA concentrations in several brain regions of the aged rats. As regards serotonin
receptors, no age-induced or cognitive-related changes have been reported in 5HT1A
receptor [14,70].
GDNF over-expression in CA1 astrocytes induced a local neurotrophic effect.
ChAT activity, indicative of acetylcholine levels, rose in hippocampus. In a study of motor
activity enhancement, two weeks of i.c.v. infusion of GDNF induced an increase in ChAT
activity in the septum, hippocampus, striatum and cortex of aged rats [69]. This study
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reported a similar enhancement of ChAT by GDNF or neural growth factor (NGF). The
trophic effects of NGF on aged cholinergic neurons have been extensively studied
[106,112]. NGF binds with high affinity to the TrkA receptor, which is mainly located on
cholinergic neurons in the basal forebrain nuclei and striatum [62]. A partial recovery of the
cognitive abilities in the Morris water maze, similar to that we obtained with GDNF, was
reported initially [39,40]. In subsequent studies, an almost complete reversal was obtained
either by a higher dosage through i.c.v. chronic infusion [41] or by NGF-secreting cell
implants at the two main cholinergic forebrain cell groups, nucleus basalis magnocellularis
and medial septum/diagonal band of Broca (MS/DB) [79]. Although hippocampus function
resulted significantly enhanced by astrocyte-secreted GDNF, we did not obtain complete
recovery of spatial learning. This could be due to a partial inability of locally expressed
GDNF to recover the function of the circuitry entering the hippocampus from cholinergic
cell bodies located in the MS/DB. A retrograde signaling of GDNF to these cell bodies [27]
may not be enough when functional terminals are already reduced. On the other hand, the
complexity of the reciprocal cholinergic connections between CA1 and MS/DB [47,95]
may modulate the functional response. In this regard, ventral CA1 that receives cholinergic
afferents from a broader MS/DB area showed a slightly higher ChAT enhancement than the
greater GDNF-expressing dorsal CA1 area.
In addition to cholinergic enhancement, GDNF secreted by transduced astrocytes
enhanced dopaminergic and serotonergic neurotransmission over control aged rats
transduced with GFP. Dopamine and serotonin levels increased without the concentration
of their metabolites rising, thus demonstrating a significant neurotransmitter synthesis
increase. High variability of dopamine level led to a lack of statistical significance for its
increase in the dorsal CA1 area, even though GDNF dopamine value nearly doubled the
GFP group value. Given the reduction of dopamine receptor function in the hippocampus
discussed above, the increased neurotransmitter levels would help to restore dopaminergic
function. On the other hand, the tissue dopamine levels obtained barely could account for
an increase of the risk of oxidative damage by dopamine auto-oxidation [21]. However, the
presence of hydroxylated adducts in hippocampus should be analyzed whenever a longer
therapy is planned. While GDNF increased serotonin levels less than dopamine it similarly
enhanced specific synaptic transmission, as long as there was no loss of serotonin receptors
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due to aging. As discussed above for the cholinergic neurotransmission, GDNF
enhancement of the dopaminergic mesencephalic afferents [44] and the serotonergic
afferents from the median raphe [83] may not be enough to fully recover the hippocampus
functionality.  To notice that studies in Parkinson’s disease models have demonstrated that
GDNF induces a higher functional recovery when acting in the striatum terminals than in
the substantia nigra dopaminergic bodies [26,65]. Therefore, an earlier and sustained
therapy of GDNF in the hippocampus would probably result in a better strategy for spatial
memory recovery than its delivery to other targets. Nonetheless, testing the GDNF effects
on other related brain areas cannot be discarded.
GDNF showed a broad neurotrophic effect and probably also enhanced other
neurotransmitters involved in learning and memory such as glutamate and GABA.
GABAergic interneurons, present in the stratum pyramidale and stratum oriens express
GFR-1 [107], lose function with aging [113]. Decrease of NMDA receptor density in the
aged CA1 region correlates with spatial learning decline [76]. GDNF has shown trophic
effects on GABAergic neurons [45] and neuroprotective effects against NMDA-mediated
excitotoxicity [92]. Therefore GDNF may directly enhance these systems or/and counteract
the alterations of the interactions between the different brain neurotransmitter systems that
contribute to aging deterioration [30,110].
The amelioration of senile neurons or damaged dysfunctional neurons in future
human therapies may need a continuous supply of trophic factor [93]. Chronic infusion of
GDNF through a catheter implanted in the brain has been assayed in Parkinson’s patients
for periods of up to several years [75], but may be accompanied by both practical and
safety problems. Gene delivery ex vivo or in vivo allows selective local diffusion of the
growth factor without undesirable side effects. Strategies in various experimental animal
models of neural diseases include the implant of either astrocytes [29,31,34], neural
progenitors [2,7,9,66] or fibroblasts [100,101] engineered to secrete GDNF. However, the
advances in the design of viral vectors convert in vivo gene therapy into an attractive
strategy for long-term delivery of trophic factors to the nervous system. Neuroprotective
effects in experimental models of neurodegenerative diseases have been obtained by direct
in vivo transfer of GDNF gene with recombinant adenoviral [1,11,24,31,68], adeno-
associated [36,65,81,123] and lentiviral vectors [17,48,54,67,124]. Replication-defective
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lentiviral vectors are safe and can sustain a strong expression of transgenes for long periods
[91]. They can efficiently transduce neurons and glial cells and cause minimal
inflammatory and immunological responses [80,125]. The combination of viral particle
pseudotyping and gene promoter facilitates targeting of specific cell types [10,28]. We
constructed a lentiviral vector pseudotyped with Mokola G protein and its gene expression
driven by the CMV promoter. This vector showed selectivity for transducing the astrocytes
in the hippocampal area of injection.
In conclusion, a short chronic delivery of GDNF in the dorsal CA1 hippocampal
astrocytes enhanced local cholinergic, dopaminergic and serotonergic transmission, leading
to improved spatial learning and memory performance in cognitively impaired aged rats.
Astrocytes proved to be an appropriated cell type for over-secreting GDNF in gene therapy
strategies. Deficiencies were not totally reverted; suggesting that GDNF paracrine action in
the CA1 area could be too restricted to obtain complete recovery of the complex behavioral
learning task. Finally, lentiviral vectors showed high efficacy, making feasible longer
chronic treatment which would probably have a better outcome. Therefore, the present
results demonstrated the therapeutic value of lentiviral vectors expressing GDNF transgene
in rat age-related cognitive decline. Further studies to explore the therapeutic possibilities
of GDNF in human aging and Alzheimer’s disease memory loss, are required.
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Figure legends
Fig. 1. Transgene expression of GFP driven by lentiviral vectors in the brain of aged rats.
Confocal micrographs of a representative transduced CA1 region (a-d) show the
immunostaining for GFP (green), for GFAP (red), the nuclei stained with bisbenzimide
(blue) and triple staining, respectively. Asterisk indicates the pyramidal layer, with the
oriens layer on the right and the stratum radiatum on the left of the images. Note that no
GFP was detected in the neuron cell bodies of the pyramidal layer. At higher magnification,
the cells secreting GFP (e) can be identified as GFAP immunostained astrocytes (f),
showing in these cells double labeling (g) (see arrows).
Fig. 2. Behavioral testing in the Morris water maze. (a) Experimental design scheduled for
the aged rats, with pre-test and test indicating the behavioral studies performed before and
after the surgical injection of the viral vectors, respectively. (b) Spatial probe trial results
distinguished impaired and unimpaired rats in the pre-test (trial 0) and showed the steadily
better performance of GDNF rats in the test (trials 1-3). Dotted line indicates chance
performance. Arrow indicates surgery. Values are the mean ± SEM, n=6-8, *p<0.05,
**p<0.01 and ***p<0.001, as compared with unimpaired rats; and #p<0.05, as compared to
the GFP group; ANOVA followed by Newman-Keules’ test. (c) The latencies to escape
during the pre-test training did not differ between GFP and GDNF rat groups. Values are
the mean ± SEM, n=6-7. (d) The latencies to escape during the test training did not differ,
either, between GFP and GDNF rat groups, Values are the mean ± SEM, n=6-7.
Fig. 3. Hippocampal regional concentration of neurotransmitters. (a) Choline acetyl
transferase (ChAT) activity, indicative of acetylcholine levels, and (b) dopamine and (c)
serotonin tissue levels. Young, 8-month old rats; GFP, 24-month old cognitively impaired rats
transduced with human green fluorescent protein in the dorsal CA1 area; GDNF, 24-month old
cognitively impaired rats transduced with human glial cell line derived neurotrophic factor in the
dorsal CA1. Numeric values are detailed in Tables 2, 3 and 4 respectively. Values are the
mean ± SEM, n=6-8, *p<0.05, **p<0.01 and ***p<0.001, as compared with unimpaired
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rats; and #p<0.05, ###p<0.001 as compared to the GFP group; ANOVA followed by
Newman-Keules’ test.
Tabla 1. Levels of GDNF after lentiviral transduction with hGDNF gene
GDNF (pg/mg tissue)
GDNF
(n=7)
GFP
(n=3)
Naïve
(n=3)
Hippocampus
dorsal CA1 288.1 ± 54.6a,b 5.6 ± 3.6 9.8 ± 3.9
CA2/3 173.3 ± 48.9a,c 4.1 ± 1.8 6.5 ± 0.8
Dentate
gyrus 52.5 ± 20.1 4.0 ± 1.1 6.3 ± 1.8
ventral
CA1 96.2 ± 44.7 7.0 ± 3.0 7.9 ± 1.2
CA2/3 58.5 ± 23.5 2.8 ± 0.7 4.9 ± 2.2
Dentate
gyrus 15.8 ± 4.0 5.5 ± 1.3 3.3 ± 1.1
Experimental groups: GDNF, right hippocampus of young rats transduced with human glial
cell line derived neurotrophic factor in the dorsal CA1 area; GFP, left hippocampus
transduced with the control vector expressing human green fluorescent protein in the dorsal
CA1; naïve, untransduced left hippocampus. Results are the mean ± SEM, n = 7, 3 and 3, for
GDNF, GFP and naïve group, respectively. Statistics: (a) significance of GDNF group as
compared to GFP or naïve group, (b) significance of dorsal CA1 as compared to all the other
regions, (c) significance of dorsal CA2/3 as compared to ventral dentate gyrus; ANOVA
followed by Newman-Keules’ test at the significance level of p<0.05.
Table 2
Brain regional activity of choline acetyl transferase.
ChAT (14C-ACh nmol/mg protein/h)
Young GFP GDNF
Hippocampus
dorsal CA1 3.97 ± 0.26 4.28 ± 0.23 4.97 ± 0.23a
CA2/3 4.42 ± 0.20 4.90 ± 0.50 5.21 ± 0.38
Dentate
gyrus 4.32 ± 0.35 3.99 ± 0.26 5.02 ± 0.21
ventral CA1 3.69 ± 0.23 3.61 ± 0.32 5.18 ± 0.17a,b
CA2/3 5.05 ± 0.29 4.54 ± 0.12 4.23 ± 0.19a
Dentate
gyrus 4.07 ± 0.28 4.50 ± 0.52 4.82 ± 0.31
Cortex Cingulate 3.60 ± 0.25 4.22 ± 0.39 5.83 ± 0.58a,b
Frontal 3.36 ± 0.30 3.26 ± 0.14 4.06 ± 0.46
Parietal 3.00 ± 0.27 3.46 ± 0.28 4.09 ± 0.81
Temporal 3.03 ± 0.24 3.20 ± 0.39 3.24 ± 0.45
Entorhinal 3.64 ± 0.24 3.31 ± 0.08 3.38 ± 0.17
Septum 6.76 ± 0.76 5.10 ± 0.12 5.47 ± 0.38
Caudate 1.82 ± 0.32 3.22 ± 0.69 2.33 ± 0.27
Experimental groups: Young, 8-month old rats; GFP, 24-month old cognitively impaired rats
transduced with human green fluorescent protein in the dorsal hippocampus CA1; GDNF, 24-
month old cognitively impaired rats transduced with human glial cell line derived neurotrophic
factor in the dorsal hippocampus CA1. Values are the mean ± SEM of 6-9 animals. Statistics:
(a) significance of GFP or GDNF groups as compared to young rats and (b) significance of
GDNF as compared to GFP group; ANOVA followed by Newman-Keules’ test at the
significance level of p<0.05.
Table 3
Brain regional concentration of dopamine and its metabolites DOPAC and HVA.
Dopamine (fmol/mg tissue) DOPAC (fmol/mg tissue) HVA (fmol/mg tissue)
Young GFP GDNF Young GFP GDNF Young GFP GDNF
Hippocampus
dorsal CA1 41 ± 6 74 ± 12 136 ± 44a 264 ± 87 180 ± 31 293 ± 79 287 ± 43 114 ± 35a 122 ± 28a
CA2/3 61 ± 12 76 ± 12 111 ± 27 260 ± 73 192 ± 53 229 ± 52 211 ± 16 117 ± 26a 123 ± 24a
Dentate
gyrus 50 ± 11 119 ± 35 217 ± 70a 249 ± 91 237 ± 37 428 ± 115 257 ± 65 144 ± 29 173 ± 30
ventral CA1 45 ± 11 67 ± 8 102 ± 37 157 ± 24 179 ± 24 214 ± 60 201 ± 26 91 ± 12 159 ± 61
CA2/3 52 ± 9 75 ± 25 91 ± 15 264 ± 61 184 ± 75 228 ± 43 254 ± 37 251 ± 103 119 ± 22
Dentate
gyrus 43 ± 10 150 ± 64 221 ± 58a 255 ± 80 313 ± 122 370 ± 74 259 ± 40 152 ± 41 196 ± 74
Cortex Cingulate 193 ± 46 279 ± 58 156 ± 33 533 ± 95 510 ± 128 364 ± 122 633 ± 47 338 ± 86a 233 ± 68a
Frontal 139 ± 58 132 ± 17 126 ± 40 354 ± 73 233 ± 43 203 ± 46 554 ± 98 164 ± 25a 115 ± 12a
Parietal 62 ± 9 93 ± 12 114 ± 21a 390 ± 113 311 ± 52 223 ± 49 776 ± 183 226 ± 27a 163 ± 40a
Temporal 701 ± 175 607 ± 149 633 ± 143 672 ± 146 501 ± 143 491 ± 47 590 ± 142 185 ± 39a 172 ± 18a
Entorhinal 299 ± 90 290 ± 64 436 ± 106 503 ± 89 323 ± 85 444 ± 47 455 ± 95 154 ± 31a 184 ± 12a
Septum 6702 ± 2156 7085 ± 8081 ± 2165 9474 ± 2485 7844 ± 2300 9907 ± 2728 4437 ± 933 2476 ± 728a 2483 ± 562a
1803
Caudate 22289 ±
3104
19901 ±
2339
19964 ± 3732 21965 ±
1829
10012 ±
2553a
11653 ± 1707a 10185 ± 850 3006 ± 613a 3040 ±
429a
Experimental groups: Young, 8-month old untransduced rats; GFP, 24-month old cognitively impaired rats transduced with human green fluorescent protein
in the dorsal hippocampus CA1; GDNF, 24-month old cognitively impaired rats transduced with human glial cell line derived neurotrophic factor in the dorsal
hippocampus CA1. Values are the mean ± SEM of 6-9 animals. Statistics: (a) significance of GFP or GDNF groups as compared to young rats; ANOVA
followed by Newman-Keules’ test at the significance level of p<0.05.
Table 3
Brain regional concentration of dopamine and its metabolites DOPAC and HVA.
Dopamine (fmol/mg tissue) DOPAC (fmol/mg tissue) HVA (fmol/mg tissue)
Young GFP GDNF Young GFP GDNF Young GFP GDNF
Hippocampus
dorsal CA1 41 ± 6 74 ± 12 136 ± 44a 264 ± 87 180 ± 31 293 ± 79 287 ± 43 114 ± 35a 122 ± 28a
CA2/3 61 ± 12 76 ± 12 111 ± 27 260 ± 73 192 ± 53 229 ± 52 211 ± 16 117 ± 26a 123 ± 24a
Dentate
gyrus 50 ± 11 119 ± 35 217 ± 70a 249 ± 91 237 ± 37 428 ± 115 257 ± 65 144 ± 29 173 ± 30
ventral CA1 45 ± 11 67 ± 8 102 ± 37 157 ± 24 179 ± 24 214 ± 60 201 ± 26 91 ± 12 159 ± 61
CA2/3 52 ± 9 75 ± 25 91 ± 15 264 ± 61 184 ± 75 228 ± 43 254 ± 37 251 ± 103 119 ± 22
Dentate
gyrus 43 ± 10 150 ± 64 221 ± 58a 255 ± 80 313 ± 122 370 ± 74 259 ± 40 152 ± 41 196 ± 74
Cortex Cingulate 193 ± 46 279 ± 58 156 ± 33 533 ± 95 510 ± 128 364 ± 122 633 ± 47 338 ± 86a 233 ± 68a
Frontal 139 ± 58 132 ± 17 126 ± 40 354 ± 73 233 ± 43 203 ± 46 554 ± 98 164 ± 25a 115 ± 12a
Parietal 62 ± 9 93 ± 12 114 ± 21a 390 ± 113 311 ± 52 223 ± 49 776 ± 183 226 ± 27a 163 ± 40a
Temporal 701 ± 175 607 ± 149 633 ± 143 672 ± 146 501 ± 143 491 ± 47 590 ± 142 185 ± 39a 172 ± 18a
Entorhinal 299 ± 90 290 ± 64 436 ± 106 503 ± 89 323 ± 85 444 ± 47 455 ± 95 154 ± 31a 184 ± 12a
Septum 6702 ± 2156 7085 ± 8081 ± 2165 9474 ± 2485 7844 ± 2300 9907 ± 2728 4437 ± 933 2476 ± 728a 2483 ± 562a
1803
Caudate 22289 ±
3104
19901 ±
2339
19964 ± 3732 21965 ±
1829
10012 ±
2553a
11653 ± 1707a 10185 ± 850 3006 ± 613a 3040 ±
429a
Experimental groups: Young, 8-month old untransduced rats; GFP, 24-month old cognitively impaired rats transduced with human green fluorescent protein
in the dorsal hippocampus CA1; GDNF, 24-month old cognitively impaired rats transduced with human glial cell line derived neurotrophic factor in the dorsal
hippocampus CA1. Values are the mean ± SEM of 6-9 animals. Statistics: (a) significance of GFP or GDNF groups as compared to young rats; ANOVA
followed by Newman-Keules’ test at the significance level of p<0.05.
Table 4
Brain regional concentration of serotonin and its metabolite 5HIAA.
5HT (fmol/mg tissue) 5HIAA (fmol/mg tissue)
Young GFP GDNF Young GFP GDNF
Hippocampus
dorsal CA1 531 ± 99 766 ± 104 1225 ± 210a,b 2259 ± 313 3097 ± 219 2787 ± 303
CA2/3 383 ± 50 656 ± 118 800 ± 136a 1992 ± 264 3045 ± 601 2881 ± 340
Dentate
gyrus 413 ± 107 91 ± 93 1230 ± 186a,b 1729 ± 169 2888 ± 414a 3454 ± 263a
ventral CA1 789 ± 199 871 ± 181 1329 ± 256 2179 ± 236 3229 ± 262a 3052 ± 345a
CA2/3 454 ± 70 815 ± 188 733 ± 110 2210 ± 259 2799 ± 493 2210 ± 278
Dentate
gyrus 535 ± 105 942 ± 235 1405 ± 229a 2458 ± 228 2660 ± 539 3268 ± 371
Cortex Cingulate 770 ± 152 1300 ± 94a 956 ± 143 1913 ± 232 3227 ± 1114 1669 ± 258
Frontal 1251 ± 158 1460 ± 226 1421 ± 203 1822 ± 158 1698 ± 244 1757 ± 221
Parietal 666 ± 136 1099 ± 187 1034 ± 181 1646 ± 203 1875 ± 304 1893 ± 237
Temporal 689 ± 104 1386 ± 313a 985 ± 137 1477 ± 208 1978 ± 156 1609 ± 112
Entorhinal 1005 ± 287 1314 ± 224 1614 ± 243 1897 ± 230 2012 ± 234 2344 ± 285
Septum 1384 ± 180 1972 ± 317 2084 ± 276 2963 ± 261 3590 ± 333 3713 ± 724
Caudate 736 ± 99 1352 ± 215a 1131 ± 152 2038 ± 153 1991 ± 240 2354 ± 300
Experimental groups: Young, 8-month old rats; GFP, 24-month old cognitively impaired rats transduced with human green fluorescent protein in the dorsal
hippocampus CA1; GDNF, 24-month old cognitively impaired rats transduced with human glial cell line derived neurotrophic factor in the dorsal
hippocampus CA1. Values are the mean ± SEM of 6-9 animals. Statistics: (a) significance of GFP or GDNF groups as compared to young rats and (b)
significance of GDNF as compared to GFP group; ANOVA followed by Newman-Keules’s test at the significance level of p<0.05.



